GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
The study is designed
- to demonstrate efficacy of AFM13 with an optimized treatment schedule
- to decide whether AFM13 warrants further investigation in a phase III clinical trial